Ankur Dhingra

Insider Reports History

Reporting-owner location: South San Francisco, CA
Latest reporting-owner signature: Robert Maynes for Ankur Dhingra
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Ankur Dhingra

Form 4 holding SVP, Chief Financial Officer

ILLUMINA, INC.

Security class: Common Stock
Shares / value: 34,264
Estimated value: $5,149,193
Report date: 05 Mar 2026
Price: $150.28
Ownership: Direct

Form 4 holding Chief Financial Officer

Summit Therapeutics Inc.

Security class: Common Stock
Shares / value: 354,958
Estimated value: $1,331,093
Report date: 26 Mar 2024
Price: $3.75
Ownership: By Dhingra Family Revocable Trust

Form 4 holding Chief Financial Officer

CareDx, Inc.

Security class: Common Stock
Shares / value: 33,146
Estimated value: $395,763
Report date: 25 Mar 2022
Price: $11.94
Ownership: Direct

Form 4 holding Chief Financial Officer

CareDx, Inc.

Security class: Common Stock
Shares / value: 5,000
Estimated value: $59,700
Report date: 25 Mar 2022
Price: $11.94
Ownership: By Dhingra Family Revocable Trust

Form 4 holding SVP, Chief Financial Officer

ILLUMINA, INC.

Security class: Performance Shares
Shares / value: 10,918
Estimated value
Report date: 05 Mar 2026
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Insider Reports Filed by Ankur Dhingra

4 ILMN

ILLUMINA, INC.

Report period: 05 Mar 2026
Transactions: 3
Transaction value: $0
Accepted by SEC: 09 Mar 2026, 17:04
Role: SVP, Chief Financial Officer
Next action: Open filing details

4 ILMN

ILLUMINA, INC.

Report period: 12 May 2025
Transactions: 1
Transaction value: +$495,381
Accepted by SEC: 14 May 2025, 16:20
Role: SVP, Chief Financial Officer
Next action: Open filing details

4 ILMN

ILLUMINA, INC.

Report period: 05 Mar 2025
Transactions: 3
Transaction value: $0
Accepted by SEC: 07 Mar 2025, 16:18
Role: SVP, Chief Financial Officer
Next action: Open filing details

3 GRAL

GRAIL, LLC

Report period: 11 Jun 2024
Transactions: 0
Transaction value: $0
Accepted by SEC: 12 Jun 2024, 18:44
Role: Director
Next action: Open filing details

4 ILMN

ILLUMINA, INC.

Report period: 06 May 2024
Transactions: 3
Transaction value: $0
Accepted by SEC: 08 May 2024, 18:17
Role: SVP, Chief Financial Officer
Next action: Open filing details

3 ILMN

ILLUMINA, INC.

Report period: 15 Apr 2024
Transactions: 0
Transaction value: $0
Accepted by SEC: 24 Apr 2024, 17:06
Role: SVP, Chief Financial Officer
Next action: Open filing details

4 SMMT

Summit Therapeutics Inc.

Report period: 26 Mar 2024
Transactions: 1
Transaction value: +$375,000
Accepted by SEC: 27 Mar 2024, 20:27
Role: Chief Financial Officer
Next action: Open filing details

4 SMMT

Summit Therapeutics Inc.

Report period: 13 Dec 2023
Transactions: 2
Transaction value: +$44,254
Accepted by SEC: 13 Dec 2023, 16:49
Role: Chief Financial Officer
Next action: Open filing details

4 SMMT

Summit Therapeutics Inc.

Report period: 07 Mar 2023
Transactions: 1
Transaction value: +$206,180
Accepted by SEC: 08 Mar 2023, 16:24
Role: Chief Financial Officer
Next action: Open filing details

4/A SMMT

Summit Therapeutics Inc.

Report period: 16 Aug 2022
Transactions: 2
Transaction value: +$36,554
Accepted by SEC: 08 Mar 2023, 15:58
Role: Chief Financial Officer
Next action: Open filing details

3 SMMT

Summit Therapeutics Inc.

Report period: 31 May 2022
Transactions: 0
Transaction value: $0
Accepted by SEC: 02 Jun 2022, 17:38
Role: Chief Financial Officer
Next action: Open filing details

4 SMMT

Summit Therapeutics Inc.

Report period: 31 May 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 02 Jun 2022, 17:29
Role: Chief Financial Officer
Next action: Open filing details

4 CDNA

CareDx, Inc.

Report period: 25 Mar 2022
Transactions: 1
Transaction value: -$47,527
Accepted by SEC: 28 Mar 2022, 19:31
Role: Chief Financial Officer
Next action: Open filing details

4 CDNA

CareDx, Inc.

Report period: 02 Feb 2022
Transactions: 2
Transaction value: $0
Accepted by SEC: 04 Feb 2022, 16:48
Role: Chief Financial Officer
Next action: Open filing details

4 CDNA

CareDx, Inc.

Report period: 24 Nov 2021
Transactions: 1
Transaction value: +$211,694
Accepted by SEC: 29 Nov 2021, 15:19
Role: Chief Financial Officer
Next action: Open filing details

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .